Onychomycosis Treatment Market Size, Industry Trends, Share and Report 2023-2028

The latest report by IMARC Group, titled “Onychomycosis Treatment Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028“,The global onychomycosis treatment market size reached US$ 3.1 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 4.3 Billion by 2028, exhibiting a growth rate (CAGR) of 5.37% during 2023-2028.

Onychomycosis, also known as tinea unguium, is a fungal infection of the toenails and fingernails that can include any component of the nail like the matrix, bed, and plate. It is associated with distortion in the shape of nails, whitish to yellow-brown discoloration, foul smell, and brittle, ragged and crumbly texture of the nails. It can be treated using various prescription and non-prescription medications and oral antifungal therapy, which aid in preventing the growth of the fungus, reducing the risk of contamination, and providing protein for the development of healthy nails.

For an in-depth analysis, you can refer sample copy of the report: https://www.imarcgroup.com/onychomycosis-treatment-market/requestsample

Onychomycosis Treatment Market Trends and Drivers:

A rising prevalence of onychomycosis among the masses represents one of the major factors bolstering the market growth around the world. Moreover, the increasing number of smokers, who are prone to develop onychomycosis, is contributing to the growth of the market. Furthermore, the rising exposure of individuals to public swimming pools and utilization of tight, contaminated, and soiled clothes, shoes, and socks is favouring the market growth. In addition, the growing traction of topical nail lacquers and ointments to maintain nail hygiene is influencing the market positively. Apart from this, the launch of water-soluble antifungal treatment solutions that can be administered orally is creating a positive outlook for the market.

Report Segmentation:

The report has segmented the market into the following categories:

Breakup by Disease Type:

  • Distal Subungual Onychomycosis
  • Proximal Subungual Onychomycosis
  • White Superficial Onychomycosis
  • Candidal Onychomycosis
  • Others

Breakup by Treatment Type:

  • Laser Therapy
  • Photodynamic Therapy
  • Drug Treatment

Breakup by Drug Class:

  • Allylamine
  • Azole
  • Griseofulvin
  • Others

Breakup by Distribution Channel:

  • Hospitals and Clinics
  • Online Stores
  • Retail Pharmacies
  • Others

Market Breakup by Region:

  • North America (United States, Canada)
  • Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, Others)
  • Europe (Germany, France, United Kingdom, Italy, Spain, Russia, Others)
  • Latin America (Brazil, Mexico, Others)
  • Middle East and Africa

Competitive Landscape with Key Player:

  • Bausch Health Companies Inc.
  • Cipla Limited
  • Dr. Reddy’s Laboratories
  • Galderma SA
  • GlaxoSmithKline PLC
  • Kaken Pharmaceutical Co. Ltd.
  • Lumenis Ltd.
  • Moberg Pharma AB
  • Novartis AG
  • Pfizer Inc.
  • The OTC Lab B.V. 

If you need specific information that is not currently within the scope of the report, we will provide it to you as a part of the customization.

About Us

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.

Contact US

IMARC Group

134 N 4th St. Brooklyn, NY 11249, USA

Email: sales@imarcgroup.com

Tel No:(D) +91 120 433 0800

United States: +1-631-791-1145 | United Kingdom: +44-753-713-2163